The immunology of multiple sclerosis

KE Attfield, LT Jensen, M Kaufmann… - Nature Reviews …, 2022 - nature.com
Our incomplete understanding of the causes and pathways involved in the onset and
progression of multiple sclerosis (MS) limits our ability to effectively treat this complex …

Treg cell-based therapies: challenges and perspectives

C Raffin, LT Vo, JA Bluestone - Nature Reviews Immunology, 2020 - nature.com
Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

[HTML][HTML] Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment

H Harjunpää, M Llort Asens, C Guenther… - Frontiers in …, 2019 - frontiersin.org
The immune system and cancer have a complex relationship with the immune system
playing a dual role in tumor development. The effector cells of the immune system can …

[HTML][HTML] Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity

M Romano, G Fanelli, CJ Albany, G Giganti… - Frontiers in …, 2019 - frontiersin.org
Regulatory T cells (Tregs) are important for the induction and maintenance of peripheral
tolerance therefore, they are key in preventing excessive immune responses and …

[HTML][HTML] The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases

A DeMaio, S Mehrotra, K Sambamurti… - Journal of …, 2022 - Springer
The adaptive immune system and associated inflammation are vital in surveillance and host
protection against internal and external threats, but can secondarily damage host tissues …

[HTML][HTML] Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications

S Yang, J Wang, DD Brand, SG Zheng - Frontiers in immunology, 2018 - frontiersin.org
Tumor necrosis factor α (TNFα) is a pleiotropic cytokine which signals through TNF receptor
1 (TNFR1) and TNF receptor 2 (TNFR2). Emerging evidence has demonstrated that TNFR1 …

[HTML][HTML] Multiple sclerosis: immunopathology and treatment update

N Dargahi, M Katsara, T Tselios, ME Androutsou… - Brain sciences, 2017 - mdpi.com
The treatment of multiple sclerosis (MS) has changed over the last 20 years. All
immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a …

tTregs, pTregs, and iTregs: similarities and differences

EM Shevach, AM Thornton - Immunological reviews, 2014 - Wiley Online Library
Summary Foxp3+ T‐regulatory cells (Tregs) are primarily generated in the thymus (tTreg),
but also may be generated extrathymically at peripheral sites (pTreg), or induced in cell …

[HTML][HTML] The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment

M Haist, H Stege, S Grabbe, M Bros - Cancers, 2021 - mdpi.com
Simple Summary Immunotherapy improved the therapeutic landscape for patients with
advanced cancer diseases. However, many patients do not benefit from immunotherapy …

Animal models of multiple sclerosis

C Procaccini, V De Rosa, V Pucino, L Formisano… - European journal of …, 2015 - Elsevier
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system (CNS) which involves a complex interaction between immune system and neural …